# OPTIMIZING SKIN CANCER DETECTION IN THE GENERAL POPULATION: AN EARLY ACCESS LESION-DIRECTED CONSULTATION

Melanoma

2,2%

Benign

76,4%

Benign

89,8%

Melanoma

9,1% SCC

6,4%

BCC

8,2%

BCC

**SCC** 4,8%

Mylle S<sup>1</sup>, Hoorens I<sup>1</sup>, Van de Maele B<sup>1</sup>, Verhaeghe E<sup>1</sup>°, Brochez L<sup>1</sup>°

### INTRODUCTION

**Systematic screening** of the general population for skin cancer has **not** been proven to be **cost-effective**. In previous studies, we observed comparable detection rates in a population-based total body examination (TBE) and a lesion-directed

screening (LDS) (2.3% versus 3.2%), the latter specifically addressing a lesion of concern meeting one of the criteria listed under 'Materials and Methods'

(1). We examined this **lesion- directed screening approach** in depth by introducing an early access consultation at our dermatology department.

Not advised a

Not advised nor referred by physician (N=186)

### **MATERIALS AND METHODS**

Patients contacting the dermatology unit with 1 to 3 lesion(s) of concern were offered an early access consultation, preferably within one week. After clinical and dermoscopic evaluation of the lesion(s) of concern, a TBE was offered. From February 2017 to April 2017 and

T-cell October 2017 to July 2019, 342 patients consullymphoma
0,5% ted, of which 297 gave consent to analyse
their data.

Advised or referred by physician (N=110)

Inclusion criteria

1-3 lesions that met one of the following criteria:

New lesion in adult (18+)

Ugly duckling Fast growing mole

Referral by nondermatologist concerning suspicious lesion Changed mole

Changed mole

Changed mole

Changed mole

fast growing mole

Lesion in worried patient already in follow-up for skin cancer

Fig. 1: detection rates illustrated by (non-)referral or advice by non-dermatologist to consult a dermatologist

## **RESULTS**

45 skin cancers have been confirmed histologically resulting in a minimum detection rate of

**13.2%**. Among these 14 were melanoma, 18 BCC, 12 SCC and 1 T-cell lymphoma correlating with minimum detection rates of 4.1%, 5.3%, 3.5% and 0.3% respectively. After TBE in patients without a malignant index lesion 3 additional BCCs were detected (detection rate of 1.2% (3/251)). A **significant higher skin cancer detection** rate was observed in **patients advised** by the general practitioner to visit a dermatologist (26/110 (23.6%) versus 19/186 (10.2%), P<0.001). Analysis of anxiety before and after the consultation, showed a significant decrease in VAS in patients without a suspicious lesion (P<0.001).




Fig. 2: VAS anxiety scores illustrated according to clinical diagnosis

| Lesion               | TBE<br>screening<br>(N=1668) <sup>1</sup> | LDS (N=248) <sup>1</sup> | Early access consultation (N=342) |
|----------------------|---|--------------------------|-----------------------------------|
| Melanoma N(%)        | 8 (0.5)                                   | 1 (0.4)                  | 14 (4.1)                          |
| NMSC N(%)            | 31 (1.9)                                  | 7 (2.8)                  | 31 (9.1)                          |
| SCC N(%)             | 30 (1.8)                                  | 7 (2.8)                  | 12 (3.5)                          |
| BCC N(%)             | 1 (0.1)                                   | 0 (0)                    | 18 (5.3)                          |
| T-cell lymphoma N(%) | 0 (0)                                     | 0 (0)                    | 1 (0.3)                           |
| Total detection rate | 39/1668 (2.3%)                            | 8/248 (3.2%)             | 45/342 (13.2%)                    |

# CONCLUSION

This study demonstrates that a lesion-directed approach in an early access consultation is feasible and delivers a high skin cancer detection rate. We believe this early access LDS may be a way to achieve cost-effective early detection of skin cancer in the general population. Future studies should address tools that can help to optimize the preselection of lesions for an early access consultation.





CONTACT
DEPARTMENT OF DERMATOLOGY
UZ GENT
+32 (0)9 332 22 87
sofie.mylle@uzgent.be

<sup>&</sup>lt;sup>1</sup> Department of Dermatology, University Hospital Ghent, Belgium

<sup>°</sup> Equal contribution